Studying the Time of
Humankind

Medytox is a company studying the time of humankind.

The Global Leader of Botulinum Toxin Industry

Medytox is a global leader in botulinum toxin industry.

Time to Neuramis

Neuramis® is a hyaluronic acid filler product made by Medytox.

Biotechnology that
changes the future

All of Medytox starts from R&D.

Newsroom

Medytox received approval of the world’s first liquid-type BTX ‘INNOTOX® 100 unit’ in domestic market from MFDS
- With the approval, Medytox secured its lineup of various capacities along with 25, 50 units…dominating the premium BTX market in advance - The utilization rate of Medytox’s 2nd plant under cGMP guidelines has increased SEOUL, SOUTH KOREA – January, 2020 – INNOTOX® 100 unit received approval in domestic market manufactured in Medytox’s second plant designed to meet cGMP of US FDA. Medytox Inc., the leading biopharmaceutical company in Korea, said on January 2 that the Ministry of Food and Drug Safety has approved to sell INNOTOX® 100 unit, the world’s first liquid-type botulinum toxin (BTX) A-Type product, in the domestic market. With this approval, Medytox has secured its lineup of various capacities along with the existing 25 and 50 units. Also Medytox has increased the utilization rate of its second plant in Osong, which exclusively manufactures BTX products under U.S. current Good Manufacturing Practice (cGMP) guidelines. INNOTOX® is the world’s first liquid type BTX A-type developed by Medytox in 2014. It enhances safety by eliminating both human serum albumin and animal-derived substances in the manufacturing process. Also INNOTOX® can be used immediately without any dilution process, further improving the convenience of treatment and having the advantage of more accurate treatment capacity calculation. "The sales approval for INNOTOX® 100 unit is significant as it has allowed the company to secure a lineup of various capacities, and help to meet consumer needs better," Medytox CEO Hyunho Jung said. "Clinical trials are underway to secure additional indications for INNOTOX® and accelerate the company's advance to the premium BTX market." The company also plans to unveil a new prefilled syringe-type BTX, Jung said. Meanwhile, Medytox signed a partnership with Allergan, the original manufacturer of Botox, in 2013 to bring BTX to the advanced market. Recently, Allergan initiated phase 3 clinical trials in both US and EU with hopes to get US marketing approval in 2022.
2020.01.03
뉴스 더보기
read more

Medytox Vision 2022

Medytox has begun to step up its efforts to achieve Vision 2022.

Sales
$1 billion
Global Biopharmaceutical Company
TOP 20

Based on integrity and open communication, Medytox is building excellent capacity and system to meet the global standard with commitment and courage.
Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value,
and to become one of the world's top 20 biopharmaceutical companies by 2022

Medytox AD/PR Video

Medytox, a pharmaceutical company expanding beyond domestic boundaries to win global recognition.
Meet us from our first step in 2000 to now and the future.

Medytox Offices & Facilities

While meeting global quality standards, Medytox has become one of the leading global companies.

Medytox Global Business Center
Medytox global business center
Medytox R&D Center (Gwanggyo)
One-Stop R&D system facility for developing new bio-drugs
Medytox Plant I (Ochang)
Korea’s first botulinum toxin production facility
and filler production facility
Medytox Plant II (Osong)
US FDA’s cGMP and Europe EMA’s EU GMP
compliant botulinum toxin production facility
Medytox Plant III (Osong)
The world’s largest botulinum toxin and filler product
production facility that implemented

* Single-use System: Using single-use sterile bags
to shorten the process

Medytox at a Glance

over 60 countries
Korea's No.1 Botulinum Toxin Market Share
Vision $1billion in Sales
More than 26 r&d Pipeline

Medytox Global Network

Starting with a Taiwan joint venture "Medytox Taiwan", Medytox established a China joint venture "Medybloom China", a Hong Kong joint venture "Medytox Hong Kong", a Thailand joint venture "MedyCeles", and a 100% owned local subsidiary "MDT International Inc." in Japan.